|
1
|
Forde PM and Ettinger DS: Targeted therapy
for non-small-cell lung cancer: past, present and future. Expert
Rev Anticancer Ther. 13:745–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asami K and Atagi S: Epidermal growth
factor receptor tyrosine kinase inhibitors for non-small cell lung
cancer. World J Clin Oncol. 5:646–659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellis PM, Morzycki W, Melosky B, Butts C,
Hirsh V, Krasnoshtein F, Murray N, Shepherd FA, Soulieres D, Tsao
MS and Goss G: The role of the epidermal growth factor receptor
tyrosine kinase inhibitors as therapy for advanced, metastatic, and
recurrent non-small-cell lung cancer: a Canadian national consensus
statement. Curr Oncol. 16:27–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nguyen NS, Neal JW and Wakelee H: Review
of the current targeted therapies for non-small-cell lung cancer.
World J Clin Oncol. 5:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosell R, Gervais R, Vergnenegre A,
Massuti B, Felip E, Cardenal F, Gomez Garcia R, Pallares C, Sanchez
JM, Porta R, et al: Erlotinib versus chemotherapy (CT) in advanced
non-small cell lung cancer (NSCLC) patients (p) with epidermal
growth factor receptor (EGFR) mutations: Interim results of the
European Erlotinib Versus Chemotherapy (EURTAC) phase III
randomized trial. J Clin Oncol. 29:abs. 7503. 2011.PubMed/NCBI
|
|
16
|
Scagliotti G and Govindan R: Targeting
angiogenesis with multitargeted tyrosine kinase inhibitors in the
treatment of non-small cell lung cancer. Oncologist. 15:436–446.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JCH, Schuler MH, Yamamoto N, O'Byrne
KJ, Hirsh V, Mok T, Lucien S Geater, Orlov SV, Tsai CM, Boyer MJ,
et al: LUX-Lung 3: A randomized, openlabel, phase III study of
afatinib versus pemetrexed and cisplatin as first-line treatment
for patients with advanced adenocarcinoma of the lung harboring
EGFR-activating mutations. J Clin Oncol. 30:abs. LBA7500. 2012.
|
|
18
|
Gridelli C, Ciardiello F, Feld R, Butts
CA, Gebbia V, Genestreti G, Favaretto AG, Wierzbicki R, Gallo C,
Perrone F, et al: Intemational multicenter randomized phase lll
study of first-line erlotinib (E)followed by second-line cisplatin
plus gemcitabine (CG) versus first-line CG followed by second-line
E in advanced non-small cell lung cancer (a NSCLC). J Clin Oncol.
28:abs. 7508. 2010.
|
|
19
|
Janjigian YY, Park BJ, Zakowski MF,
Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J and Azzoli
CG: Impact on disease-free survival of adjuvant erlotinib or
gefitinib in patients with resected lung adenocarcinomas that
harbor EGFR mutations. J Thorac Oncol. 6:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neal JW, Pennell NA, Govindan R, Heist RS,
Shaw AT, Muzikansky A, Jänne PA, Lynch TJ, Azzoli CG and Sequist
LV: The SELECT study: A multicenter phase II trial of adjuvant
erlotinib in resected epidermal growth factor receptor (EGFR)
mutation- positive non-small cell lung cancer (NSCLC). ASCO Annual
Meeting Proceedings (Post-Meeting Edition). J Thor Oncol. 30:abs.
7010. 2012.
|
